Your browser is no longer supported. Please, upgrade your browser.
BCEL Atreca, Inc. daily Stock Chart
Atreca, Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own17.30% Shs Outstand21.29M Perf Week31.35%
Market Cap465.61M Forward P/E- EPS next Y-4.01 Insider Trans- Shs Float14.50M Perf Month45.61%
Income-43.90M PEG- EPS next Q-0.71 Inst Own84.50% Short Float1.95% Perf Quarter-
Sales- P/S- EPS this Y-37.80% Inst Trans145.43% Short Ratio1.93 Perf Half Y-
Book/sh0.04 P/B546.75 EPS next Y9.10% ROA- Target Price25.50 Perf Year-
Cash/sh10.32 P/C2.12 EPS next 5Y- ROE- 52W Range10.29 - 23.38 Perf YTD21.16%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-6.46% Beta-
Dividend %- Quick Ratio26.50 Sales past 5Y- Gross Margin- 52W Low112.54% ATR2.23
Employees85 Current Ratio26.50 Sales Q/Q- Oper. Margin- RSI (14)68.45 Volatility16.09% 16.74%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.30 Prev Close22.06
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume146.08K Price21.87
Recom1.30 SMA2051.93% SMA5039.29% SMA20039.29% Volume189,437 Change-0.86%
Jul-15-19Initiated Stifel Buy $28
Jul-15-19Initiated Evercore ISI Outperform
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $23
Aug-17-19 07:30AM  Stanford University Now Owns Stakes in Uber and Pinterest Stock
Aug-13-19 04:05PM  Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire +25.78%
Jul-15-19 02:22PM  Stifel: Atreca Offers Attractive Oncology Drug Development Play Benzinga
Jul-11-19 08:00AM  Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel GlobeNewswire
Jun-20-19 11:16AM  Atreca Opens For Trade Benzinga
Jun-19-19 09:40PM  Atreca Announces Pricing of Initial Public Offering GlobeNewswire
08:20AM  Atreca IPO: What You Need To Know Benzinga
Jun-17-19 10:07AM  IPO Outlook For The Week: Biotechs And A Grocery Outlet Benzinga
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca, Inc. was founded in 2010 and is headquartered in Redwood City, California.